Method of manufacturing a drug-eluting endocardial lead utilizing silicone elastomer as a drug carrier

• US 7,174,221 B1
• Filed: 12/12/2003
• Issued: 02/06/2007
• Est. Priority Date: 07/11/2001
• Status: Expired due to Term

• Current Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Inventors: Chitre, Yougandh, Doan, Phong D., Helland, John R., Chen, Cole H.
• Primary Examiner(s): Pezzuto; Robert E.
• Assistant Examiner(s): DROESCH, KRISTEN L
• Application Number:
  US10/736,082
• Time in Patent Office: 1,152 Days
• Field of Search: None
• US Class Current: 607/120
• CPC Class Codes: A61N 1/0568 with drug delivery

Abstract

A drug-eluting endocardial lead and method of manufacture. The silicone elastomer of the present invention is ideally suited to a manufacturing environment due to its extended pot life and decreased curing time. A preferred silicone elastomer is comprised of a multi-part mixture having at least a base portion and a curing portion. Additionally, since curing does not begin until the base and curing portions are combined, the mixing can be physically undertaken closer to the location of the endocardial lead and the curing “clock” does not start until the mixing occurs and external heat is applied. Since the silicone elastomer formed by base and curing components have improved the pot life and curing characteristics, the mixture is suitable for mixing with a steroid and then dispensing into an endocardial lead tip thus eliminating current design limitations imposed by current art while concomitantly minimizing manufacturing costs.

Claims

1. A method of manufacturing an endocardial lead, the method comprising:

combining an inflammation-reducing drug with a drug carrying silicone elastomer to form a mixture thereof;

securing the endocardial lead to a jig;

dispensing the mixture to a distal portion of the endocardial lead; and

allowing the mixture to cure at the distal portion of the endocardial lead;

wherein allowing the mixture to cure comprises elevating the temperature of the jig to cure the mixture.

2. The method of claim 1 wherein the applying the mixture to a distal portion comprises applying the mixture within a chamber of the endocardial lead.

3. The method of claim 1 wherein the endocardial lead is a passive lead.

4. The method of claim 1 wherein the endocardial lead is an active fixation lead.

5. The method of claim 1 wherein the inflammation-reducing drug is a steroid.

6. The method of claim 1 wherein the combining an inflammation-reducing drug with a drug carrying silicone elastomer comprises:

combining a wetting fluid component and the inflammation-reducing drug to form a first mixture;

combining the first mixture and a base component to form a second mixture;

combining the second mixture and a curing component to form a third mixture;

applying the third mixture to a distal portion of the endocardial lead; and

curing the third mixture at a predetermined temperature.

7. The method of claim 6 wherein the predetermined temperature is in the range of about 40 degrees C. to 75 degrees C.

8. The method of claim 6 wherein the base component is dimethylsiloxane polymer and a reinforcing silica, and wherein the curing component is a platinum catalyst.

9. A method of manufacturing an endocardial lead, the method comprising:

combining an inflammation-reducing drug with a drug carrying silicone elastomer to form a pourable mixture thereof;

providing a chamber at the distal portion of the endocardial lead;

securing the endocardial lead to a jig;

dispensing the pourable mixture into a distal portion of the endocardial lead; and

curing the pourable mixture in the distal portion of the endocardial lead;

wherein the dispensing the pourable mixture comprises dispensing the mixture within the chamber; and

wherein the curing comprises elevating the temperature of the jig to cure the pourable mixture within the chamber.

10. The method of claim 9 wherein the endocardial lead is a passive fixation lead.

11. The method of claim 9 wherein the endocardial lead is an active fixation lead.

12. A method of manufacturing a drug-eluting lead containing drug-eluting means for dispensing a drug, the lead having a distal tip, the method comprising the steps of:

providing the endocardial lead;

securing the endocardial lead to a jig;

combining an inflammation-reducing drug with a drug carrying silicone elastomer to form a mixture thereof;

applying the mixture to the distal tip of the lead; and

allowing the mixture to cure in place in the lead;

wherein allowing the mixture to cure in place in the lead comprises elevating the temperature of the jig to cure the mixture.

13. The method of claim 12 wherein the step of combining comprises the steps of:

combining a wetting fluid component and the inflammation-reducing drug to form a first mixture;

combining the first mixture and a base component to form a second mixture;

combining the second mixture and a curing component to form a third mixture; and

applying the third mixture into the distal tip of the lead; and

curing the third mixture applied to the tip at a predetermined temperature.

14. The method of claim 13 wherein the curing step comprises the step of elevating the temperature to the predetermined value being in the range of about 40 degrees C. to 75 degrees C.

15. The method of claim 13 wherein the step of combining to form a first mixture comprises the step of providing a steroid for the inflammation-reducing drug.

16. The method of claim 13 wherein the step of combining to form a second mixture comprises the step of providing a mixture of dimethylsiloxane polymer and a reinforcing silica for the base component.

17. The method of claim 13 wherein the step of combining to form a third mixture comprises the step of providing a platinum catalyst for the curing component.

18. The method of claim 14 wherein the curing step comprises setting the predetermined temperature to 55 degrees C.